Cargando…
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
Immune response to two SARS-CoV-2 mRNA vaccine doses among kidney transplant recipients (KTRs) is limited. We aimed to evaluate humoral and cellular response to a third BNT162b2 dose. In this prospective study, 190 KTRs were evaluated before and ∼3 weeks after the third vaccine dose. The primary out...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068869/ https://www.ncbi.nlm.nih.gov/pubmed/35529596 http://dx.doi.org/10.3389/ti.2022.10204 |
_version_ | 1784700309365325824 |
---|---|
author | Yahav, Dafna Rahamimov, Ruth Mashraki, Tiki Ben-Dor, Naomi Steinmetz, Tali Agur, Timna Zingerman, Boris Herman-Edelstein, Michal Lichtenberg, Shelly Ben-Zvi, Haim Bar-Haim, Erez Cohen, Hila Rotem, Shahar Elia, Uri Margalit, Ili Zvi, Benaya Rozen |
author_facet | Yahav, Dafna Rahamimov, Ruth Mashraki, Tiki Ben-Dor, Naomi Steinmetz, Tali Agur, Timna Zingerman, Boris Herman-Edelstein, Michal Lichtenberg, Shelly Ben-Zvi, Haim Bar-Haim, Erez Cohen, Hila Rotem, Shahar Elia, Uri Margalit, Ili Zvi, Benaya Rozen |
author_sort | Yahav, Dafna |
collection | PubMed |
description | Immune response to two SARS-CoV-2 mRNA vaccine doses among kidney transplant recipients (KTRs) is limited. We aimed to evaluate humoral and cellular response to a third BNT162b2 dose. In this prospective study, 190 KTRs were evaluated before and ∼3 weeks after the third vaccine dose. The primary outcomes were anti-spike antibody level >4160 AU/ml (neutralization-associated cutoff) and any seropositivity. Univariate and multivariate analyses were conducted to identify variables associated with antibody response. T-cell response was evaluated in a subset of participants. Results were compared to a control group of 56 healthcare workers. Among KTRs, we found a seropositivity rate of 70% (133/190) after the third dose (37%, 70/190, after the second vaccine dose); and 27% (52/190) achieved levels above 4160 AU/ml after the third dose, compared to 93% of controls. Variables associated with antibody response included higher antibody levels after the second dose (odds ratio [OR] 30.8 per log AU/ml, 95% confidence interval [CI]11–86.4, p < 0.001); and discontinuation of antimetabolite prior to vaccination (OR 9.1,95% CI 1.8–46.5, p = 0.008). T-cell response was demonstrated in 13% (7/53). In conclusion, third dose BNT162b2 improved immune response among KTRs, however 30% still remained seronegative. Pre-vaccination temporary immunosuppression reduction improved antibody response. |
format | Online Article Text |
id | pubmed-9068869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90688692022-05-05 Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study Yahav, Dafna Rahamimov, Ruth Mashraki, Tiki Ben-Dor, Naomi Steinmetz, Tali Agur, Timna Zingerman, Boris Herman-Edelstein, Michal Lichtenberg, Shelly Ben-Zvi, Haim Bar-Haim, Erez Cohen, Hila Rotem, Shahar Elia, Uri Margalit, Ili Zvi, Benaya Rozen Transpl Int Health Archive Immune response to two SARS-CoV-2 mRNA vaccine doses among kidney transplant recipients (KTRs) is limited. We aimed to evaluate humoral and cellular response to a third BNT162b2 dose. In this prospective study, 190 KTRs were evaluated before and ∼3 weeks after the third vaccine dose. The primary outcomes were anti-spike antibody level >4160 AU/ml (neutralization-associated cutoff) and any seropositivity. Univariate and multivariate analyses were conducted to identify variables associated with antibody response. T-cell response was evaluated in a subset of participants. Results were compared to a control group of 56 healthcare workers. Among KTRs, we found a seropositivity rate of 70% (133/190) after the third dose (37%, 70/190, after the second vaccine dose); and 27% (52/190) achieved levels above 4160 AU/ml after the third dose, compared to 93% of controls. Variables associated with antibody response included higher antibody levels after the second dose (odds ratio [OR] 30.8 per log AU/ml, 95% confidence interval [CI]11–86.4, p < 0.001); and discontinuation of antimetabolite prior to vaccination (OR 9.1,95% CI 1.8–46.5, p = 0.008). T-cell response was demonstrated in 13% (7/53). In conclusion, third dose BNT162b2 improved immune response among KTRs, however 30% still remained seronegative. Pre-vaccination temporary immunosuppression reduction improved antibody response. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9068869/ /pubmed/35529596 http://dx.doi.org/10.3389/ti.2022.10204 Text en Copyright © 2022 Yahav, Rahamimov, Mashraki, Ben-Dor, Steinmetz, Agur, Zingerman, Herman-Edelstein, Lichtenberg, Ben-Zvi, Bar-Haim, Cohen, Rotem, Elia, Margalit and Zvi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Yahav, Dafna Rahamimov, Ruth Mashraki, Tiki Ben-Dor, Naomi Steinmetz, Tali Agur, Timna Zingerman, Boris Herman-Edelstein, Michal Lichtenberg, Shelly Ben-Zvi, Haim Bar-Haim, Erez Cohen, Hila Rotem, Shahar Elia, Uri Margalit, Ili Zvi, Benaya Rozen Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title | Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title_full | Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title_fullStr | Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title_full_unstemmed | Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title_short | Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study |
title_sort | immune response to third dose bnt162b2 covid-19 vaccine among kidney transplant recipients—a prospective study |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068869/ https://www.ncbi.nlm.nih.gov/pubmed/35529596 http://dx.doi.org/10.3389/ti.2022.10204 |
work_keys_str_mv | AT yahavdafna immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT rahamimovruth immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT mashrakitiki immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT bendornaomi immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT steinmetztali immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT agurtimna immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT zingermanboris immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT hermanedelsteinmichal immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT lichtenbergshelly immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT benzvihaim immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT barhaimerez immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT cohenhila immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT rotemshahar immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT eliauri immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT margalitili immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy AT zvibenayarozen immuneresponsetothirddosebnt162b2covid19vaccineamongkidneytransplantrecipientsaprospectivestudy |